Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Thompson J, Yee S, Troxel A, Savitch S, Fan R, Balli D, Lieberman D, Morrissette J, Evans T, Bauml J, Aggarwal C, Kosteva J, Alley E, Ciunci C, Cohen R, Bagley S, Stonehouse-Lee S, Sherry V, Gilbert E, Langer C, Vachani A, Carpenter E. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clinical Cancer Research 2016, 22: 5772-5782. PMID: 27601595, PMCID: PMC5448134, DOI: 10.1158/1078-0432.ccr-16-1231.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCtDNA next-generation sequencingResistance mutationsNext-generation sequencingTissue sequencingAdvanced non-small cell lung cancerActionable EGFR mutationsCell lung cancerProgressive diseaseConsecutive patientsCtDNA sequencingTargetable driversLung cancerClinical trialsDisease progressionEGFR mutationsUltra-deep sequencingPatient managementExperimental therapiesTumor genotypingCtDNA samplesTissue biopsiesPatientsAccurate diagnosisBlood collection